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Milan, Italy; and Richmond, Virginia
Objectives This study sought to test the functional exercise capacity and endothelial function in a cohort of chronic heart
failure (CHF) patients treated with chronic type 5 phosphodiesterase (PDE5) inhibitor.
Background In CHF, endothelial dysfunction is involved in muscle underperfusion, ergoreflex oversignaling, and exercise venti-
lation inefficiency. Inhibition of PDE5 by improving endothelial dysfunction might be beneficial.
Methods Stable CHF patients were randomly assigned to placebo (23 patients) or sildenafil at the dose of 50 mg twice
per day (23 patients) in addition to their current drug treatment for 6 months, with assessments (at 3 and 6
months) of endothelial function by brachial artery flow-mediated dilatation (FMD), cardiopulmonary exercise test-
ing, and ergoreflex response.
Results In the sildenafil group only, at 3 and 6 months we observed reduction of systolic pulmonary artery pressure
(from 33.7 to 25.2 mm Hg and 23.9 mm Hg), ergoreflex effect on ventilation (from 6.9 to 2.3 l·min1 and 1.9
l·min1), ventilation to CO2 production slope (VE/VCO2, from 35.5 to 32.1 and 29.8), and breathlessness (score)
(from 23.6 to 16.6 and 17.2), and an increase of FMD (from 8.5% to 13.4% and 14.2%), peak VO2 (from 14.8 to
18.5 ml·min1·kg1 and 18.7 ml·min1·kg1), and ratio of VO2 to work rate changes (from 7.7 to 9.3 and 10.1).
All changes were significant at p  0.01. In the sildenafil group, a significant correlation was found at 3 and 6
months between changes in FMD and those in ergoreflex. Changes in ergoreflex correlated with those in peak
VO2 and VE/VCO2 slope. No adverse effects were noted except for flushing in 3 patients.
Conclusions In CHF, improvement in exercise ventilation and aerobic efficiency with sildenafil is sustained and is significantly
related with an endothelium-mediated attenuation of exercising muscle oversignaling. Chronic sildenafil seems
to be a remedy based on CHF pathophysiology and devoid of remarkable adverse effects. (J Am Coll Cardiol
2007;50:2136–44) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.078t
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hn chronic heart failure (CHF), much attention has lately
een focused on the skeletal muscle as an elicitor of
utonomic outflow, a mediator of fatigue, and a source of
xcessive ventilatory stimulus (1,2), which is subjectively
nterpreted as breathlessness sensation. Abnormal skeletal
uscle signaling (3) due to stimulation by muscle metabolic
yproducts (ergoreflex) is becoming a prominent concept in
ur quest to understand and treat this disease, and inter-
entions effective in reducing the peripheral stimulus have
een repeatedly advocated (2–5).
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ccepted July 23, 2007.It is conceivable that muscle reflex contribution to ven-
ilation can be reduced by improving endothelial function
nd up-regulating muscle perfusion because: 1) during
xercise an endothelium-mediated vasodilation modulates
eurogenic vasoconstriction and up-regulates muscle perfu-
ion (6–8); 2) agonist-induced and shear-stress nitric oxide–
ediated vasodilation are decreased in skeletal muscle
irculation of patients with CHF compared with age-
atched normal subjects (9 –11); and 3) there is a link
etween endothelial function and ergoreflex activity
12,13).
See page 2145
Sildenafil is a specific inhibitor of type 5 phosphodiester-
se (PDE5) that increases nitric oxide availability and nitric
xide-mediated vasodilation in CHF patients (9). Interest
as therefore been focused on the potential of sildenafil to
e beneficial in CHF (14). In acute studies, sildenafil
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November 27, 2007:2136–44 Sildenafil in CHFncreased myocardial contractility (15), blunted adrenergic
timulation (16), reduced left ventricular afterload (15), and
mproved lung diffusion capacity (17), pulmonary hemody-
amics at rest (17) and on exertion (18), and exercise
entilation efficiency and aerobic performance (17,18).
We investigated whether: 1) an endothelium-mediated
odulation of muscle oversignaling is a mechanism whereby
ildenafil can reduce exercise hyperventilation and heighten
xercise capacity (19); and 2) the compound maintains this
bility during chronic use without adverse effects, and if so,
hether there is a rational basis for larger, long-term thera-
eutic trials with PDE5 inhibition in CHF.
ethods
tudy and control patients. The trial included 46 male
atients, whose age was younger than 65 years to minimize
he influence of age on endothelial function (20), and who
ere referred to the outpatient Cardiopulmonary Unit at
an Paolo Hospital, Milan, and to the Department of
hysical Therapy at Virginia Commonwealth University for
valuation of CHF. They were in stable clinical condition
ompatible with New York Heart Association functional
lass II to III. The CHF was caused by ischemic or
diopathic cardiomyopathy. Eligibility criteria were consent
o participate in the study after receiving detailed informa-
ion about procedures, possible clinical benefits, and risks;
egative exercise stress test prior to study initiation; forced
Clinical Characteristics of the Study Participant
Table 1 Clinical Characteristics of the Stud
n
Age, yrs
Gender, male/female
Body mass index, kg/m2
Etiology, IHD/DCM
Quality of life
Breathlessness
Fatigue
Emotional function
Blood tests
Total cholesterol, mmol·l1
Triglycerides, mmol·l1
Drug Therapy
Average Da
Dose (mg
Digoxin 0.25
Furosemide 50
Aldactone 25
ACE inhibitors
Enalapril 10
Ramipril 5
Angiotensin-1 receptor blockers
Losartan 75
Beta-blockers
Metoprolol 83
Carvedilol 16ACE  angiotensin-converting enzyme; DCM  dilated cardiomyopathy; IHDxpiratory volume in 1 s/forced
ital capacity ratio 70%; left
entricular ejection fraction
45%, determined by echocardi-
graphy. Patients were not re-
ruited if they were not able to
omplete a maximal exercise test
r if they had systolic blood pres-
ure 140 and 110 mm Hg,
iabetes mellitus, therapy with ni-
rate preparations, history of silde-
afil intolerance, significant lung
r valvular diseases, neuromuscular
isorders, atrial fibrillation (12),
laudication, or peripheral vascular
isease. Participants were not in-
olved in any physical training
rogram and were not receiving
gents that could affect endothelial function (statins, antioxi-
ant vitamins, xanthine oxidase inhibitors) or ergoreflex (aspi-
in) (21). They had never smoked or were ex-smokers of at
east 8 months (22), with a pack-year index of smoking of10.
heir carboxyhemoglobin was 2%. All were symptomatic
uring exercise and limited by breathlessness and muscle
atigue. Current drug treatment of heart failure was stable and
as that prescribed by the referring physician, including
iuretics, ACE inhibitors, digoxin, beta-blockers, angiotensin
ticipants
Placebo Group Sildenafil Group
23 23
63 4 62 3
23/0 23/0
27 2 26 1
10/13 11/12
21.4 4.3 23.6 5.2
22.1 6.4 19.6 5.0
30.8 7.1 32.6 8.4
5.5 0.3 5.7 0.5
1.9 0.2 2.0 0.3
7 5
15 16
12 12
10 12
8 7
4 4
6 6
10 8
Abbreviations
and Acronyms
CHF  chronic heart failure
CPET  cardiopulmonary
exercise testing
FMD  flow-mediated
dilation
PDE5  type 5
phosphodiesterase
VCO2  carbon dioxide
production
VD/VT  dead space/tidal
volume ratio
VE  ventilation
VO2  oxygen uptake
WR  work rates
y Par
ily
) ischemic heart disease.
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Sildenafil in CHF November 27, 2007:2136–44eceptor blockers, or aldactone (Table 1). All subjects gave their
ritten consent to the study, and none was excluded after study
nclusion. The trial was approved by the local ethics commit-
ees and conformed to the Declaration of Helsinki. These
atients’ data have not appeared in any previous publication
rom our groups.
ardiopulmonary exercise testing (CPET). Patients per-
ormed a standard, progressively increasing (personalized
amp protocol) work rate (WR) CPET to maximum toler-
nce on a cycle ergometer in the upright position. Gas
xchange measurements (Cardiopulmonary Metabolic Cart,
ensormedics Vmax Spectra, Yorba Linda, California) were
btained at rest (2 min) and during 2 min of unloaded leg
ycling at 60 rpm, followed by a progressively increasing
R exercise. Heart rate, electrocardiogram (ECG), and
uff blood pressure were measured and recorded. Minute
entilation (VE), oxygen uptake (VO2), carbon dioxide
utput (VCO2), dead space/tidal volume ratio (VD/VT) and
ther exercise variables were computer-calculated breath-
y-breath, interpolated second-by-second, and averaged at
0-s intervals. The V-slope analysis method was used to
easure the anaerobic threshold (AT). Patients were en-
ouraged to exercise to exhaustion (VCO2/VO2 1.1) and
topped exercise as a result of breathlessness and/or fatigue.
he slope of the relationship between VE and VCO2
VE/VCO2) was calculated, by simple regression of data
ollected throughout exercise, as an established index of
entilatory efficiency (23). We also assessed the VO2 at AT
nd the rate at which VO2 increased per WR (VO2/WR)
s an indicator of aerobic efficiency (24). Peak VO2 was
omputed as the average VO2 values measured in the last
0 s of exercise.
ascular studies. Brachial artery flow-mediated vasodila-
ion (FMD) was investigated as previously reported (13). In
rief, images were obtained by the same investigator
hroughout the study with a high-resolution ultrasound
1-MHz linear-array transducer (Philips Medical Systems,
A, Best, the Netherlands). After obtaining the clearest
rtery view, the transducer was held in position by a
tereotactic clamp. Vasodilation was measured as the max-
mal change in brachial artery diameter during hyperemia
fter release of a cuff inflated (50 mm Hg greater than
ystolic pressure for 5 min) on the forearm. Diameter was
easured in millimeters, coincident with the R waves on the
CG for 6 cardiac cycles, and the 6 measurements were
veraged. The vasodilator response from repeated studies
as evaluated by a technician who was blinded to the
atient treatment and time sequence; images were stored on
video format and were then analyzed with image analysis
oftware.
Flow velocity was measured by pulsed Doppler with
ange gate (1.5 mm) in the artery center. The cuff was
nflated for 5 min and then rapidly deflated. A 90-s scan was
aken immediately after deflation. Blood flow was calculated
y multiplying the velocity time integral of the Doppler
ignal by the cross-sectional area of the vessel and the heart fate. Reactive hyperemia was calculated as absolute maximal
hange in flow during reactive hyperemia compared with
aseline. The FMD was calculated as percent (reactive hyper-
mia baseline/baseline 100) maximal increase in diameter
eached in 90 s after cuff release compared with baseline.
rgoreflex assessment. The ergoreflex was evaluated using
he method described by Scott et al. (25). A maximal
oluntary handgrip test was measured as the greatest of the
eak forces produced by 3 brief maximal handgrip contrac-
ions preliminarily performed before the test. Ergoreceptor
timulation consisted of a 2-min VE recording during rest,
ollowed by a handgrip session that was performed twice in
andom order, according to the following protocol: 1) a
-min session of rhythmic handgrip achieved by squeezing
he balloon of a sphygmomanometer (30 squeezes/min) at
0% of the predetermined capacity, followed by a 3-min
ontrol recovery; and 2) the same protocol was followed
oon after interruption of exercise by 3 min of blood stasis
n the exercise arm by inflating an upper arm biceps
ourniquet to 30 mm Hg greater than systolic blood pressure
t the beginning of recovery. The difference of the changes
n VE between the mean resting values and the average of
he second and third minute recovery with and without
ost-handgrip circulatory occlusion represented the ergore-
ex component of the ventilatory response to exercise.
uality of life (QOL). Quality of life was assessed using a
HF questionnaire (26) that has a total of 16 questions: 5
o assess breathlessness, 4 to assess fatigue, and 7 to assess
motional function of daily living. The answers may be
cored from 1 (worst function) to 7 (best function), with a
aximum score of 112 (best QOL) and a minimum score of
6 (worst QOL).
tudy protocol. The 46 enrolled patients were randomized
o receive placebo or oral sildenafil 50 mg 3 times per day
27) in addition to their baseline pharmacological treatment.
he trial duration was 6 months, and the study design is
hown in Figure 1. Patients were admitted to the hospital
nd were maintained on their current therapy prescribed by
he referring physician. After routine laboratory work,
ardiac and pulmonary function evaluation, and ECG
olter monitoring, they performed a preliminary familiar-
zation with the procedures for evaluation of brachial FMD
nd of the ergoreflex and with a graded CPET to determine
eak VO2. On the next day, in each patient these tests were
epeated, left ventricular ejection fraction and pulmonary
rtery systolic pressure (by recording tricuspid jet velocity)
ere measured, and results were taken as the reference ones.
n the next morning the response to sildenafil was assessed
n all participants to verify whether the agent was similarly
ffective in patients randomized to placebo as in candidates
o the active preparation treatment. Patients’ morning doses
f their usual medications were withheld. After an overnight
ast, in a quiet room, after 15 min rest, 50 mg sildenafil was
dministered orally. Two hours later, to coincide with the
xpected peak in the hemodynamic response (28), ejection
raction, pulmonary systolic pressure, brachial artery FMD,
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November 27, 2007:2136–44 Sildenafil in CHFrgoreflex, and CPET were reevaluated in that order. Then,
atients were discharged and a 6-month double-blind trial
f sildenafil (23 patients) versus placebo (23 patients) was
egun with pulmonary systolic pressure, FMD, ergoreflex
ctivation and exercise performance, echocardiography, and
CG Holter monitoring reassessed at 3 and 6 months in
oth groups (Fig. 1). Physical examination and ECG were
erformed, symptoms were recorded, and QOL was evalu-
ted. For each patient, compliance was assessed by the pill
ount method at monthly return visits.
tatistical analysis. Randomization was performed on
he basis of computer-generated random numbers. As-
uming a 10% decrease of VE/VCO2 slope and a 20%
ncrease in peak VO2 (16), a test with an alpha of 0.05 and
power of 0.90 would require a sample size of 19
atients. Including a 20% safety margin for patients lost
o follow-up, we aimed at the recruitment of 23 study
atients. An equal number of similar patients were enrolled
s control patients. Values are expressed as mean  SD.
atient characteristics at baseline were compared using
hi-square analysis.
The acute incremental changes from baseline with silde-
afil were analyzed using a paired t test. Repeated-measures
nalysis of variance and the Neuman-Keuls multiple com-
arison procedure were used to test differences between pre-
nd post-treatment evaluations. The relationship of changes
n FMD versus those in ergoreflex, as well as those between
rgoreflex and VE/VCO2 slope and peak VO2, were assessed
sing the Pearson correlation coefficient. Comparisons of
he various phases of the ergoreflex test (resting phase,
andgrip exercise, recovery) between the 2 groups, and
ithin the same group between with and without circulatory
cclusion, were performed using the paired and unpaired
test as appropriate.
A value of p 0.05 was considered significant. Statistical
nalyses were performed by the STATA 7.0 package (Stata
Figure 1 Study Design
Measurements at day 2 were performed at baseline, and those at day 1 were
dose of sildenafil (50 mg) in all participants. CHF  chronic heart failure; CPET orp., College Station, Texas). tesults
one of the patients was withdrawn for major adverse
vents. Twenty patients in the placebo group and 21 in the
ildenafil group completed the trial (Fig. 1). Three and 2
atients in group 1 and group 2, respectively, were lost to
ollow-up during the last 3 months (Fig. 1), for family
easons or because they moved from the town. The 2 cohorts
ere similar regarding age, gender, body mass index, drug
herapies, cholesterol and triglyceride plasma concentra-
ions, and QOL (Table 1). Cohorts were also homogeneous
ith respect to left ventricular ejection fraction, systemic
nd pulmonary artery pressures, and brachial artery FMD.
o significant difference was evidenced in exercise perfor-
ance (VO2 at AT and peak VO2), ventilatory efficiency
VE/VCO2 slope), VD/VT, aerobic efficiency (VO2/WR),
rachial artery FMD, and ergoreflex effect on VE. Values of
hese functions are reported in Table 2.
After randomization, the acute responses to sildenafil
ere evaluated in all participants to test sensitivity to the
rug. The responsiveness was comparable between the 2
ohorts (Table 2), and consisted of a similar significant
ncrease in ventilation efficiency, brachial artery FMD, peak
O2 and VO2 at AT, and aerobic efficiency, and of a
ignificant decrease of the pulmonary artery systolic pressure
SPP), ergoreflex effect on VE, and VD/VT. Heart rate,
ystemic arterial pressure, left ventricular ejection fraction,
nd reactive hyperemia to brachial artery occlusion were not
ignificantly affected.
Table 3 reports values of the aforementioned variables
nd QOL score at baseline and with the active drug and
lacebo, at 3 and 6 months of follow-up. Compared with
aseline, measurements performed after 3 months of active
reatment showed a significant reduction of SPP (25.2%),
rgoreflex (66.6%), VE/VCO2 slope (14.0%), peak
D/VT (17.3%), breathlessness (29.6%), and emo-
med after a single oral
pulmonary exercise testing.perfor
cardioional function (19.3%). A parallel increase of brachial
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Sildenafil in CHF November 27, 2007:2136–44rtery FMD (57.6%), peak VO2 (25.0%), VO2 at AT
38.1%), and VO2/WR (20.7%) was observed. Ab-
olute values at 3 months were similar to those achieved in
he acute study after a single oral dose of sildenafil (Table 2).
n the group receiving placebo, no significant change from
aseline was observed in any of these functions after 3
onths.
At 6 months, compared with the 3-month assessments,
here were no variations with placebo, and a trend of SPP,
rgoreflex, VE/VCO2 slope, FMD, peak VO2, and VO2/
WR toward a further improvement with sildenafil. Vari-
tions observed at 6 months did not reach statistical signif-
cance when compared with those at 3 months; however,
hen compared with acute sildenafil, SPP, brachial artery
MD, VE/VCO2 slope, and VO2/WR were consistently
etter (p  0.01). Heart rate and systemic arterial pressure
id not vary significantly during the trial in the 2 groups.
Figure 2 is a graphic expression of VE in both the study
atients and control patients, at rest, during handgrip and
etaboreflex test, in the baseline and during follow-up.
Baseline brachial artery FMD, in patients in the active
reatment group as well as in those in the placebo group, was
nversely related with the baseline ergoreflex component of
he ventilatory response to handgrip (Fig. 3). On the
ontrary, FMD changes at 3 and 6 months were inversely
elated with changes in ergoreflex in the sildenafil group
nly (Fig. 3). In this group, and not in that receiving
lacebo, changes in ergoreflex were inversely related with
hose in peak VO2 and positively related with those in
irculatory and Respiratory Variables at Baseline and After Acute Sn Patients Randomized to Pl cebo and in Pat ents Randomized to
Table 2 Circulatory and Respiratory Variables at Baseline andin Patients Randomized to Placebo and in Patients Ra
Plac
Baseline
Hemodynamics
Heart rate, beats/min 71.9 2.6
LV ejection fraction, % 31.9 3.3
Systemic arterial pressure, mm Hg
Systolic 124.8 6.2
Diastolic 75.2 2.8
Pulmonary artery systolic pressure, mm Hg 31.9 2.7
Vascular assessment
Brachial artery FMD, % 7.8 0.7
Brachial artery reactive hyperemia, ml·min1 261.0 18.0
CPET variables
Peak VO2, ml·min
1·kg1 15.3 1.8
VO2 at AT, ml·min
1·kg1 8.9 3.1
VE/VCO2 slope 34.4 2.7
Peak RER 1.16 0.09
Peak VD/VT 0.22 0.03
VO2WR 7.9 2.0
Arterial O2 saturation, % 97.8 0.6
Ergoreflex effect on VE, l·min
1 7.3 1.4
p  0.01 versus baseline.
AT  anaerobic threshold; CPET  cardiopulmonary exercise testing; FMD  flow-mediated dila
O2  oxygen uptake; WR  work rate.E/VCO2 slope, at 3 and 6 months (Fig. 4). pIn 7 patients at the end of the 6-month sildenafil
rescription, withdrawal assessments at 24 h did not docu-
ent significant differences in any variable from values
hile on treatment. The exact durability of effect, however,
emains to be defined.
We did not observe any major adverse effect attributable
o the research procedures or to sildenafil. In particular,
olter monitoring ruled out development of hyperkinetic
rrhythmias in patients receiving the PDE5 inhibitor, no
isual abnormalities (blurred vision or color vision abnor-
alities) were reported during follow-up, and liver enzymes
nd creatinine levels remained unchanged for the duration
f the study. Minor adverse reactions consisted of flushing
n 3 patients in group 1 and in 4 patients in group 2. No
atient developed initial dose hypotension or headache or
howed sexual disturbances. During the trial there were no
eaths in either group; there were 2 hospitalizations in the
lacebo group, both because of atrial fibrillation, and no
ospitalizations in the active treatment arm.
iscussion
he aims of the present investigation were: 1) to give
vidence that the ability of sildenafil to improve CHF
ymptoms and exercise performance (17–19) is persistent
uring chronic utilization; 2) to probe whether modulation
f exercising muscle oversignaling (ergoreflex) may be a
echanism; and 3) to provide a rational basis for larger
ong-term therapeutic trials with PDE5 inhibitors in CHF
afilnafil
Acute Sildenafil
ized to Sildenafil
roup Sildenafil Group
Sildenafil Baseline Sildenafil
72.7 4.6 73.2 2.1 72.1 5.5
33.0 2.5 30.6 3.0 32.8 2.7
121.4 7.0 126.7 5.4 121.3 7.6
72.8 4.0 76.7 3.3 73.2 5.7
25.4 3.0* 33.7 3.1 26.8 3.2*
11.6 0.8* 8.5 0.6 12.7 0.7*
273.0 15.0 272.0 16.0 284.0 12.0
19.2 1.4* 14.8 1.5 18.3 1.7*
12.5 3.7* 9.2 3.3 13.3 2.9*
31.0 3.9* 35.5 4.7 32.3 3.6*
1.15 0.07 1.14 0.07 1.15 0.08
0.19 0.01* 0.23 0.01 0.20 0.02*
9.4 1.8* 7.7 1.8 9.1 1.9*
98.3 0.5 98.1 0.4 98.0 0.5
2.4 0.5* 6.9 1.2 2.2 0.6*
 left ventricular; RER  respiratory exchange ratio; VD/VT  dead space to tidal volume ratio;ildenSilde
After
ndom
ebo Gatients.
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November 27, 2007:2136–44 Sildenafil in CHFIn the active treatment arm, breathlessness and pulmo-
ary artery pressure were attenuated and exercise perfor-
ance and ventilatory efficiency were improved both at 3
nd at 6 months. Compared with baseline, these variables
ere steady in the placebo arm, and this discrepancy was not
xplained by different drug responsiveness. Group assign-
ent was performed randomly, the trial was double blind,
nd the cohorts were fairly homogeneous with respect to
ge, gender, somatic characteristics, and current drug ther-
py. The evidence is convincing that improvement of CHF
ymptoms and of the underlying pathophysiology in the
ildenafil group is attributable to the drug, and that such an
bility persists during chronic treatment. This is consonant
ith results of PDE5 inhibition in pulmonary hypertension,
howing that efficacy persists as long as the application is
ontinued (27–31). At 6 months, compared with 3 months,
he trend of symptoms and physiological variables was
oward further improvement, without reaching statistical
ignificance. Nonetheless, the trend was uniform, and no-
ably, improvement was significant when values at 6 months
ere compared with those in the acute study, suggesting
hat the responsiveness to PDE5 inhibition may become
reater with continuous application.
DE5 inhibition and exercise ventilatory efficiency. An
xcessive ventilatory response to exercise is objectively de-
ected by an increase in the VE/VCO2 slope and is perceived
irculatory and Respiratory Variables and Quality of Lifet Baseline and After 3 and 6 Months of Treatment With Placebo o
Table 3 Circulatory and Respiratory Variables and Quality of Lifat Baseline and After 3 and 6 Months of Treatment W
Placebo G
Baseline 3 Month
Hemodynamics
Heart rate, beats/min 71.9 2.6 71.5 2
LV ejection fraction, % 31.9 3.3 30.8 2
Systemic arterial pressure, mm Hg
Systolic 124.8 6.2 123.1 4
Diastolic 75.2 2.8 74.0 3
Pulmonary artery systolic pressure, mm Hg 31.9 2.7 34.5 2
Vascular assessment
Brachial artery FMD, % 7.8 0.7 7.6 0
Brachial artery reactive hyperemia, ml·min1 261.0 18.0 274 3
CPET variables
Peak VO2, ml·min
1·kg1 15.3 1.8 14.9 1
VO2 at AT, ml·min
1·kg1 8.9 3.1 9.0 2
VE/VCO2 slope 34.4 2.7 34.2 2
Peak RER 1.16 0.09 1.14 0
Peak VD/VT 0.22 0.03 0.23 0
VO2WR 7.9 2.0 7.7 2
Arterial O2 saturation, % 97.8 0.6 97.9 0
Ergoreflex effect on VE, l·min
1 7.3 1.4 7.2 1
Quality of life
Breathlessness 21.4 4.3 22.2 5
Fatigue 22.1 6.4 22.8 6
Emotional function 30.8 7.1 32.1 6
p  0.01 versus baseline value. †p  0.01 versus corresponding value in the placebo group.
VCO2  carbon dioxide production; VE  ventilation; other abbreviations as in Table 2.s breathlessness. Increased VE might help to keep normal i2 alveolar tension, at the price, however, of premature
xhaustion of the ventilatory reserve. The pathogenesis of
nefficient VE may be: reduced perfusion of ventilated lung,
arly acidosis, lung interstitial space distension and
-receptor activation, abnormal chemoreflex and baroreflex
ontrol, overactive skeletal muscle signaling, excessive pul-
onary capillary pressure increase, and interstitial fluid
ransition on exercise (1,2,32,33). It can be inferred that
mproved pulmonary hemodynamics and cardiac output
ould amend many of these disorders, thus augmenting
xercise capacity and reducing ventilation.
A hallmark of CHF is an increase in impedance to right
nd left ventricular ejection due to increased pulmonary and
ystemic vascular resistances. A therapeutic goal in CHF to
mprove overall cardiac performance is reduction in pulmo-
ary vascular resistance (34). Sildenafil in CHF acts pre-
ominantly as a pulmonary vasodilator during exercise (21).
eduction in pulmonary vascular resistance leads to im-
roved ventricular ejection fraction, cardiac output, exercise
erformance (18), and diminished fluid flux transition to the
lveolar interstitium (17). On the other hand, heightened
ystemic vascular tone contributes to diminished skeletal
uscle perfusion that facilitates early anaerobic metabolism
n exercise (5).
We explored the hypothesis that endothelial dysfunction
n CHF may promote muscle oversignaling and PDE5
ive Drug
acebo or Active Drug
Sildenafil Group
6 Months Baseline 3 Months 6 Months
73.8 3.1 73.2 2.1 74.3 4.2 72.4 3.8
30.4 3.6 30.6 3.0 33.6 3.2 34.7 2.8
122.2 5.8 126.7 5.4 122.3 5.6 124.4 4.5
74.1 3.7 76.7 3.3 74.7 3.2 75.2 3.0*
33.7 3.1 33.7 3.1 25.2 2.4*† 23.9 3.1*†
8.1 0.8 8.5 0.6 13.4 0.7*† 14.2 0.5*†
269 26.0 272.0 16.0 286 21.0 291.0 18.0
15.1 1.5 14.8 1.5 18.5 1.6*† 18.7 1.7*†
8.8 3.1 9.2 3.3 12.9 2.8 13.1 3.2
34.5 3.7 35.5 4.7 32.1 3.5 29.8 2.7*
1.15 0.07 1.14 0.07 1.15 0.06 1.16 0.08
0.22 0.01 0.23 0.01 0.19 0.02*† 0.20 0.01*
7.8 1.9 7.7 1.8 9.3 1.9*† 10.1 1.8*†
98.1 0.6 98.1 0.4 98.4 0.3 98.2 0.4
7.5 0.9 6.9 1.2 2.3 1.3*† 1.9 1.5*†
24.1 5.2 23.6 5.2 16.6 5.3*† 17.2 4.5*†
21.5 5.4 19.6 5.0 18.6 4.8 20.7 6.2
34.1 7.8 32.6 8.4 26.3 7.7*† 25.0 8.4*†r Act
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Sildenafil in CHF November 27, 2007:2136–44ardiac and pulmonary hemodynamics, but also by influenc-
ng signaling from the periphery. Several facts strengthen
his hypothesis: 1) Baseline FMD in the study patients was
ower than values recorded by the same methods in normal
ubjects (35), and was similar to that observed in hyperten-
ion and diabetes (13), diseases with well-established endo-
helial dysfunction. 2) Brachial artery endothelial function
as persistently increased with sildenafil (FMD was in-
reased by more than 50% and 60% at 3 and 6 months,
espectively). 3) The ergoreflex effect on VE was decreased
y more than 80%. 4) The amount of O2 utilized per unit
ncrease in work rate (VO2/WR) was increased, suggest-
ng an improved O2 diffusion from the capillary to mito-
hondria or a facilitated working muscle perfusion. 5) There
as an inverse baseline correlation of brachial artery FMD
ith the ergoreflex component of the ventilatory response to
xercise, as well as of changes of the former with changes of
he latter after sildenafil. 6) The variations in the ergoreflex
entilatory component significantly correlated with those in
he VE/VCO2 slope.
This interpretation provides a reasonable explanation for
he enduring efficacy of the compound on breathlessness,
he dominant symptom in patients with CHF. It is con-
eivable, but so far unproven, that other basic mechanisms
videnced in acute studies, such as increased myocardial
ontractility (15), improved pulmonary hemodynamics and
ight ventricular function (18), enhanced alveolar gas dif-
using capacity (17), and beta-adrenergic modulation (36),
ay also be involved in benefits of chronic PDE5 inhibition.
Figure 2 Ergoreflex Assessment
Graphic expression of ventilation (VE) at rest (2 min), during handgrip (5 min), and
6-month treatment in patients receiving placebo and in patients receiving sildenafionfirmatory studies, however, are needed. oA better exercising muscle perfusion, a delayed exhaus-
ion of the ventilatory reserve that postpones exercise
nterruption, and a reduced impedance to left ventricular
jection (16) may well explain the correlation observed, both
t 3 and 6 months, between changes in the ergoreflex
omponent of VE to exercise and those in peak VO2.
Another aim of this study was to define whether a
rolonged use of sildenafil produces adverse effects. The
ossibility of an inadequate gas exchange and arterial oxygen
esaturation with PDE5 inhibition (37), an event that
ight be undesired in CHF patients, has been reported.
ur results, however, are not consistent with the occurrence
f some oxygen desaturation (38). Sildenafil was well
olerated, and development of hyperkinetic arrhythmias, or
ignificant changes in heart rate and blood pressure, were
ot observed. The more frequently reported side effect was
ushing, and its incidence was similar to that reported in
ther controlled trials (9).
tudy limitations. Some limitations should be critically
iscussed. Cardiovascular drugs were not titrated during
he study, and maximal tolerated doses of beta-receptor
lockers or renin-angiotensin system inhibitors were
ossibly not achieved. The study, however, was not aimed
t providing patients with the best medical treatment, but
t probing whether sildenafil adds benefits when com-
ined with the current drug treatment, and an endothelial
ysfunction modulating effect may be a mechanism. All
nvestigated patients were men. This may represent an
dditional shortcoming. Another issue was the exclusion
recovery (3 min) of metaboreflex test, in the baseline and after 3- and
0.01 versus no occlusion. §p  0.01 versus patients receiving placebo.during
l. *p f patients taking statins or aspirin, drugs that are known
t
t
b
m
m
w
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November 27, 2007:2136–44 Sildenafil in CHFo reduce mortality in ischemic cardiomyopathy. Because
hey can affect endothelium or the ergoreflex, and possi-
ly conceal the effects of sildenafil, we judged it ethically
Figure 3 Correlation Analyses
Correlation analyses between brachial artery flow-mediated dilatation (FMD) and the ergore
(solid triangles) and in the sildenafil group (open triangles) as well as between ch
VE  ventilation.
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Figure 4 Correlation Analyses
Correlation analyses between changes from baseline in the ergoreflex component
oxygen uptake (VO ) in the placebo and sildenafil groups at 3- (open circles) and 62ore acceptable to enroll patients whose current treat-
ent did not include these compounds rather than to
ithdraw them for the trial.
mponent of the ventilatory response to handgrip at baseline in the placebo group
of the 2 variables at 3- (open circles) and 6-month (solid circles) treatment.
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h (solid circles) treatment. VCO  carbon dioxide production; V  ventilation.flex co
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Sildenafil in CHF November 27, 2007:2136–44onclusions
n CHF, prolonged use of sildenafil improved the nitric
xide-mediated vasodilation, tempered the peripheral stim-
lus to hyperventilation, heightened ventilatory efficiency
nd exercise performance, and was associated with the
forementioned side effects. These results, along with the
ork of several other investigators (39), suggest that larger
ong-term trials in CHF patients with utilization of PDE5
nhibition should be considered.
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